Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

Schizophrenia remains one of the most severe medical diseases. Current dopamine modulating first-generation and second-generation antipsychotics target mainly positive symptoms, but not/inadequately negative and cognitive symptoms. Additional challenges include non-adherence and adverse effects, esp...

Full description

Saved in:

Bibliographic Details
Published in:	CNS spectrums Vol. 24; no. S1; pp. 38 - 69
Main Authors:	Krogmann, Amanda, Peters, Luisa, von Hardenberg, Laura, Bödeker, Katja, Nöhles, Viktor B., Correll, Christoph U.
Format:	Journal Article
Language:	English
Published:	New York, USA Cambridge University Press 01.08.2019
Subjects:	Alzheimer's disease Amino acids Anesthesia Antipsychotics Cannabidiol CME Review Article Dopamine FDA approval Headaches Insomnia Mental depression Mortality Nanocrystals Narcotics Nausea Pathophysiology Psychosis Psychotropic drugs Quality of life Schizophrenia Sodium Treatment resistance Schizophrenia antipsychotics psychopharmacology randomized controlled trials phases 2 and 3
ISSN:	1092-8529, 2165-6509
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!